Attend the FierceBiotech Executive Breakfast at JP Morgan
Joni us on January 8th at the Fairmont in San Francisco. Reserve your seat today.
The investment positions the Chinese antibody discovery shop to move the most advanced assets in its oncology pipeline into human testing.
Venture capital firm Novo Holdings says it is looking to fuel more early- and late-stage biotechs.
A quiet immuno-oncology startup that just began clinical tests and a rare disease are both looking to raise funding on the U.S. IPO market.
The IPO will enable MorphoSys to pump $225 million into the development of MOR208 to establish the anti-CD19 antibody as a rival to CAR-T therapies.
The series A equips NMD to see whether the efficacy seen in models of myasthenia gravis and amyotrophic lateral sclerosis translates into the clinic.
Dracen will advance drugs that stifle a tumor's energy source and boost the immune response to cancer.
The drug discovery-stage company wants to tune the metabolism of immune cells to change their behavior.
Beacon Capital's incubator will offer up to $50 million in seed funding, as well as office and lab space.
The biotech unveiled plans to sell 9 million shares hours before Kerrisdale Capital’s attack and abandoned them hours after it hit.
The funds will carry TCR2 into 2021, allowing it to bring its lead asset through clinical proof of concept.